Funding for preventive AIDS vaccine research decreased by 5.6 percent to US$845 million. The public sector accounted for 79 percent of overall funding at US$667 million, with the US public sector leading contributions at US$624.7 million or 93 percent of all public funding. European investment in preventive vaccines R&D decreased by six percent, from US$38.5 million in 2016 to US$32.5 million, signaling the lowest levels of European investment since 2001. Philanthropic contributions decreased by US$5.7 million, down to US$120 million in 2017, with BMGF remaining the largest philanthropic funder of vaccine research at US$108 million. The commercial sector contributed US$57 million, representing a six percent increase from the previous year.
In 2017, investments for AIDS vaccines were allocated mostly to preclinical research (43.6 percent), followed by clinical trials (34 percent) and basic research (17.6 percent). These allocations are reflective of the increasing focus on preclinical research since 2015, with lesser investment recorded for clinical trials.